COVID-19 assay kit CoVAMA96

infectionIgASARS-COV-2

The Microblot-Array assay is intended for the diagnosis, monitoring and screening of SARS-CoV-2 (COVID-19) infection using IgA antibodies in human serum, plasma or dry blood spot in the general population. The qualitative, semi-quantitative and quantitative automated assay is designed for professional use in a laboratory. Description: • Used Antigen: combination of selected parts of the specific antigens of SARS-CoV-2 (NCP, RBD, Spike S2, E, ACE2, PLPro protein) and antigens for exclusion cross-reactivity with other endemic coronaviruses (MERS-CoV, SARS-CoV, HCoV 229E Np, HCoV NL63 Np). • Recombinant and highly purified antigens are applied in the form of microdots (spots) in triplets to a nitrocellulose membrane in a microtiter well format. • If specific antibodies are present in the sample, they will bind to the respective antigens. • The complex is labelled with Conjugate and detected through a colour reaction with substrate (BCIP/NBT). • The kit enables 96 tests. • Short incubation periods, total assay time: approximately 1.5 h. • Each individual test includes control spots, which serves to check functionality and sensitivity of the sets, and also the spots for checking the presence of the conjugate. • Positive controls included enabling validation of the tests. • For quantitative evaluation the wells contain calibration spots. • All reagents supplied are ready to use. • The kit may be used sequentially for smaller batches of samples (reagents are provided in sufficient quantities). • Evaluation using Microblot-Array reader and the appropriate software.